Off-Label Reprint Dissemination Is Evidence Of Unlawful Intent - FDA
Executive Summary
Dissemination of off-label journal article reprints and texts is evidence of an intent to illegally introduce products into commerce for unapproved uses, FDA said in its Nov. 22 rebuttal brief to Washington Legal Foundation v. Henney appellate litigation.